Vertex Pharmaceuticals, Inc.

Schering Corporation

Schering-plough Corporation

Minzhang Chen

Gerald J Tanoury

Anantha R Sudhakar

John E Cochran

Valdas Jurkauskas

Jeonghan Park

Andrew D Jones

Juergen Weber

Ingyu Jeon

William W Leong

David Joseph Guerin

John R Snoonian

Martin Trudeau

Philip L Nyce

Xiaojing Yang

Michael D Green

Suhan Tang

George S K Wong

Eugene John Vater

Weidong Tong

Ramani R Raghavan

Maria M Tamarez

Adam R Looker

George S Wong

Young Chun Jung

Daw-long Albert Kwok

Raymond E Forslund

Fucheng Zhang

Bosco D'Sa

Christopher Nielsen

Francois Maltais

Robert B Perni

Youssef L Bennani

Gregor Zlokarnik

Dinesh Gala

Ilia A Zavialov

Tong Xiao

Gary M Lee

Hoa N Nguyen

Juan Antonio Gamboa

Vilas Hareshwar Dahanukar

Cecilia A Orr

Andrew J Goodman

Xiongwei Shi

Man Zhu

Tetsuo Iwama

Daw-Jong Kwok

Tong Gan

Bosco A D'sa

The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.

Processes and intermediates

This invention relates to processes and intermediates for the preparation of an alpha-amino beta-hydroxy acid of Formula 1 wherein the variables R, R'and Rare defined herein and the compound of Formula 1 has an enantiomeric excess (ee) of 55% or greater.

Processes and intermediates for preparing steric compounds

The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.

This invention relates to processes and intermediates for the preparation of salts of deuterated, enantiomericallv enriched alpha-amino beta-hydroxy acids of Formula 1 wherein the variables R,R'and R&#x2032;are defined herein, and wherein the process may comprise the steps of forming a salt of a compound of Formula 1, and crystallizing said salt to give a compound of greater than 55% enantiomeric excess.

Deuterated hepatitis C protease inhibitors

In one embodiment, the present application relates to a process of making a compound of formula I. and to certain intermediate compounds that are made within the process of making the compound of formula I.

[object Object]

In one embodiment, the present application relates to a process of making a compound of formula I: and to certain intermediate compounds that are made within the process of making the compound of formula I.

Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof

Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates for salts thereof

Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl

Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof

In one embodiment, the present application relates to a process of making a compound of formula I:and to certain intermediate compounds that are made within the process of making the compound of formula I.

Growing community of inventors

Plainsboro, NJ, United States of America

Minzhang Chen